ABVC Sets October 28 Vote on 5.2M-Share Equity Plan and Related-Party Land Deal
ABVC sits 46% above its 52-week low of $0.707.
Summary
ABVC's final proxy sets an October 28 special meeting to vote on a new equity incentive plan with a ~5.17M-share pool, ratification of 600,000 advisor shares, and a related-party land acquisition from a Board member for up to 1.6M shares.
Key Events · Corporate Governance and Compliance · ABVC
-
Special Meeting Set for October 28
Shareholders of record as of September 14, 2026 will vote on three proposals at a virtual meeting; 26,694,476 shares are outstanding and entitled to vote.
-
2026 Equity Incentive Plan Pool
The new plan would reserve 1,169,201 shares plus 15% of shares outstanding on the meeting date — an illustrative 5,173,372 shares — with a 5% annual evergreen increase beginning January 1, 2027.
-
Related-Party Land Acquisition
Proposal 3 authorizes up to 1,600,653 shares at no less than $1.00 per share to acquire Taiwan properties from Board member Shuling Jiang, who currently owns 3,735,572 shares (~14%) and could reach ~18.86% if the maximum is issued.
-
Independent Appraisal Values
ZMRE appraised the Taoyuan Lands at NT$10,948,541 (~US$339,048) and the Hualien Property at NT$9,146,467 (~US$283,243), for an aggregate of NT$20,095,008 (~US$622,291); the final purchase price remains subject to negotiation.
Analysis · ABVC · Life Sciences
ABVC BioPharma's definitive proxy finalizes three shareholder votes for a special meeting on October 28, 2026. The 2026 Equity Incentive Plan would create an award pool of roughly 5.17 million shares — about 19% of the 26.7 million shares outstanding — with an automatic 5% annual top-up starting in 2027. The land acquisition from Board member Shuling Jiang would issue up to 1.6 million shares at no less than $1.00 per share, potentially lifting her stake from 14% to nearly 19%. Independent appraisals value the Taiwan properties at about US$622,000, but the final purchase price and share count remain unnegotiated. Against a backdrop of minimal cash and a going-concern warning from the Q2 10-Q, these equity-based transactions represent meaningful potential dilution for existing holders.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABVC was trading at $1.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.1M. The 52-week trading range was $0.71 to $3.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.